Patients with Prehypertension - Do we have Enough Evidence to Treat them?

ISSN: 1875-6212 (Online)
ISSN: 1570-1611 (Print)

Volume 13, 6 Issues, 2015

Download PDF Flyer

Current Vascular Pharmacology

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 23rd of 60 in Peripheral Vascular Disease
  • 84th of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Dimitri P. Mikhailidis
Academic Head, Department of Clinical Biochemistry
Royal Free Hospital Campus
University College London Medical School
University College London (UCL)
Pond Street
London, NW3 2QG

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.966
5 - Year: 2.960

Patients with Prehypertension - Do we have Enough Evidence to Treat them?

Current Vascular Pharmacology, 12(4): 586-597.

Author(s): Michalska Marta, Alberto Zanchetti, Nathan D. Wong, Jolanta Malyszko, Jacek Rysz and Maciej Banach.

Affiliation: Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Zeromskiego 113; 90-549 Lodz, Poland.


In 2003, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure established a definition of a new category of BP levels called ‘prehypertension’ (preHT) that included individuals with a systolic BP of 120–139 mm Hg or a diastolic BP of 80–89 mm Hg. Patients with preHT were considered to be at increased risk for progression to hypertension and in individuals with BP in the range 130/80 to 139/89 mmHg the risk of developing hypertension was twice as high as in subjects with lower values. Still then there has been a large debate whether the introduction of preHT was based on evidence and as a consequence, it was fully justified. It has been suggested that the term prehypertension may in many subjects create anxiety and a need for unnecessary medical visits and examinations. This group of patients is also very heterogeneous and it has been pointed out that subdividing preHT group into individuals with normal BP and high normal BP would much better correspond to the continuum of BP risk for CV disease. Finally, despite some data suggesting the potential benefits of antihypertensive therapy in patients with preHT (high normal BP), there are still no hard evidences on the outcome reduction by giving antihypertensive drugs in these individuals.


Blood pressure, cardiovascular risk, high normal blood pressure, hypertension, prehypertension, risk stratification.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 12
Issue Number: 4
First Page: 586
Last Page: 597
Page Count: 12
DOI: 10.2174/15701611113119990126

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science